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Abstract
Background: Peutz-Jeghers syndrome (PJS) is caused by mutations in the tumor suppressor gene, STK11, and is
characterized by gastrointestinal hamartomas, melanin spots on the lips, and an increased risk of developing cancer.
Methods: Blood samples were collected from two unrelated Chinese PJS families totaling 20 individuals (9 male
and 11 females), including 6 PJS patients. The entire coding region of the STK11 gene was amplified by
polymerase chain reaction and analyzed by direct sequencing.
Results: A novel mutation, c.904C > T, in exon 7 was identified in both families. A C > T substitution changed
codon 302 from CAG (glutamine) to TAG (stop), truncating the STK11 protein, thus leading to the partial loss of the
kinase domain and complete loss of the a-helix C-terminus. Furthermore, one PJS patient from each family was
diagnosed with a visceral cancer, a colon cancer and a liver cancer respectively.
Conclusion: We predict that this novel mutation, p.Q302X, is most likely responsible for development of the PJS
phenotype and may even contribute to malignancy.
Background
Peutz-Jeghers Syndrome (PJS; MIM#175200) is a rare
autosomal dominant disorder characterized by gastroin-
testinal hamartomatous polyps, mucocutaneous pigmen-
tation, and an increased risk for the development of
gastrointestinal (GI) and various extra-GI malignancies
[1,2]. The relative cancer risk has been estimated to be
9-18 times higher in PJS patients than the general popu-
lation [3,4].
Mutations in the serine-threonine kinase 11 (STK11/
LKB1, MIM#602216) gene on chromosome 19p13.3
have been considered to be the major cause of PJS [5,6].
The gene is divided into nine exons that encode a 433
amino acid protein, which acts as a tumour suppressor.
Mutation detection rates of 10-94% have been achieved
at different centers, depending on the screening method,
with considerable uncharacterized genetic heterogeneity
remaining in this syndrome [2,7]. Most mutations are
frameshift or nonsense changes, which result in an
abnormal truncated protein and the consequent loss of
kinase activity [8]. However, the STK11 mutation
spectrum and genotype-phenotype correlation are still
poorly understood.
Here, we report a novel nonsense mutation, c.904C >
T (p.Q302X), in exon 7 from two unrelated Chinese PJS
families that subsequently developed colon cancer and
liver cancer, respectively.
Methods
Family study
Family 1, from Guangdong province, China, consisted of
three generations affected with PJS, including two
female and two male individuals (Figure 1A). The pro-
band (II:6) died from colon adenocarcinoma at 61 years
of age. Family 2, from Hongkong, China, included two
PJS patients (Figure 1B). The proband (III:2) in that
family underwent abdominal surgery three times due to
intussusception and obstruction of the small intestine
from Peutz-Jeghers polyps when he was 16, 23, and 25
years old. The mucocutaneous pigmentation faded gra-
dually after his third surgery, but was still visible on his
lips and buccal mucosa at the time of this study. His
mother (II:2) presented no obvious symptoms until the
time of liver cancer diagnosis at 45 years of age. The
clinical features of the affected individuals are summar-
ized in Table 1.
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characteristic mucocutaneous pigmentation, the pre-
sence of hamartomatous polyps in the gastrointestinal
tract, and a family history of PJS. Patients need to fulfill
two of these three criteria for a clinical diagnosis of the
disease [9]. This study was approved by the Medical
Ethics Committee, Nanfang Hospital of Southern Medi-
cal University, and informed consent was obtained from
all participating individuals.
Mutation detection
Genomic DNA was extracted from peripheral blood
using the QiAamp DNA Blood Midi Kit (Qiagen, Hil-
den, Germany). PCR primers were designed by Primer
3.0 (http://frodo.wi.mit.edu/primer3/) to amplify the
STK11 (GeneBank NM_000455) coding regions and
intron-exon boundaries. Details of primer sequences
and PCR conditions are available upon request. The
PCR products were then sequenced in both directions
on an ABI 3730 XL Automated DNA Sequencer
(Applied Biosystems, Foster City, CA) with the ABI Big-
Dye Terminator v3.1 cycle sequencing kit. Standard
nomenclature (http://www.hgvs.org/mutnomen/) was
used to describe sequence variations, with +1 corre-
sponding to the A of the ATG translation initiation
codon of GeneBank NM_000455 for STK11.
All patients and available family members underwent
STK11 germline mutation testing to confirm co-segrega-
tion of the mutation with the disease. In order to rule
out polymorphisms and to confirm the pathogenic
effects of variations, 100 chromosomes from 50 unre-
lated healthy individuals were also screened for the pre-
sence of the mutation.
Structural predictions of the wide-type and mutant STK11
protein
The homology modeling programs, SWISS MODEL
(http://swissmodel.expasy.org//SWISS-MODEL.html)
and CPH models, (http://www.cbs.dtu.dk/services/
CPHmodels/) were used to develop an appropriate
model to mimic the effects of the mutated region.
Results
Direct sequencing of the STK11 gene showed a C-to-T
transversion of nucleotide 904 in exon 7 in these two
unrelated families, which altered the wild-type sequence
A) Family   1 .                                       B ) Family 2. 
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Figure 1 Pedigree of the families with PJS. Roman numerals indicate generations and arabic numbers indicate individuals. Squares = males,
circles = females. Affected individuals are denoted by solid symbols and unaffected individuals are denoted by open symbols. A slash denotes
that the individual is deceased. The initial proband is indicated by an arrow, and participants in the DNA analysis are marked with an asterisk.
Table 1 Characteristics of affected individuals in two Chinese PJS families.
Individual Family 1 Family 2
I : 2 II : 6 III : 3 III : 4 II : 2 III : 2
Sex FM F M F M
Age at onset of mucocutaneous pigmentations unknown 2 years 3 years 3 years 6 months First year
Age at onset abdominal symptoms 34 22 14 4 No 15
Age* 34* 61* 27 23 45* 26
Anemia unknown Yes Yes Yes No Yes
Rectal bleeding unknown Yes Yes Yes No Yes
Rectal prolapse unknown Yes Yes No No Yes
Number of operations for intussusception (Age) 0 1 22 y 1 15 y 1 19 y 0 3 16, 23, 25 y
Cause of death Intussusception Colon cancer - - Liver cancer -
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Page 2 of 5CAG (glutamine) to the mutant sequence TAG (stop) at
codon 302, and resulted in a truncation of the STK11
protein (Figure 2). Our structural prediction revealed
that this mutation leads to partial loss of the kinase
domain and complete loss of the C-terminal end of the
a-helix (Figure 3). This mutation has not yet been
described in the literature.
All affected patients carried this novel mutation, but
none of their unaffected relatives or normal controls
had the mutation. Since the mutation clearly co-segre-
gated with the disease phenotype in these two families,
and the mutation was predicted to affect the expression
of the STK11 gene product, we concluded that this
mutation is disease-specific for these kindreds and not a
polymorphic variant of the STK11 gene. Both families
are from the southern part of China, and therefore it is
probable that this mutation has a common origin, even
though the two families were screened at different
centers.
Discussion
The STK11 protein is mainly comprised of three major
domains: an N-terminal non-catalytic domain that con-
tains the nuclear localization signal, a catalytic kinase
domain that is important for ATP binding, and a C-term-
inal non-catalytic regulatory domain that contains a pre-
nylation motif (CAAX-box) [10]. Codons 49-309 encode
the catalytic kinase domain. The C-terminal non-catalytic
region of the STK11 protein is encoded by exon 8 and 9,
and encompasses amino acids 309-433. In these two Chi-
nese families, the mutation, c.904C > T (p.Q302X),
results in the premature termination of the 433 amino
acid protein at codon 302, which leads to partial loss of
the kinase domain and complete loss of the C-terminal
regulatory domain (CRD). With this mutation, patient
II:6 in family 1 developed colon adenocarcinoma at 60
years of age and died one year later, and patient II:2 in
family 2 died from liver cancer at 45 years of age. These
findings suggest that the novel mutation, p.Q302X, is
Wild- t y p e                             c o don 302, Glu 
 
 
M u t a n t   t y p e                            c o d o n   3 0 2 ,   s t o p  
Figure 2 The germline nonsense mutation of the STK11 gene. Arrows indicate the position of the mutation and the underlines highlight
the codon containing the mutation. The wide-type sequence CAG (glutamine) is altered to the mutant sequence TAG (stop) at codon 302,
which leads to truncation of the STK11 protein.
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phenotype and may even contribute to malignancy.
Although the exact function of STK11 remains largely
unknown, studies suggest that it plays a role in cell sig-
naling and apoptosis [11]. Development of the PJS phe-
notypes is believed to be due to the elimination of the
kinase activity of STK11, which is associated with a loss
of growth suppression function [12]. Recently, several
proteins, including p53, Cdc37, Hsp90, and PTEN,
which are responsible for cancer syndromes when
mutated or involved in cancer pathways, were reported
to interact with the kinase domain of STK11; however,
the protein interaction domains have not been mapped
[13]. Accordingly, the interaction domain for one of
these proteins may be localized to codon 302, and there-
fore could explain the high cancer risk of mutations
within this site. Moreover, the C-terminal domain of
STK11 is important for binding STRAD, which is a pro-
tein that is possibly involved in MAPK signaling, control
of the AMPK pathway (a key regulator of cellular meta-
bolism), and control of cell polarity [14,15]. Taken
together, these data suggest that the novel STK11 muta-
tion, c.904C > T (p.Q302X), which was found in two
unrelated Chinese PJS families, causes partial loss of the
kinase domain and complete loss of the C-terminal
domain, and may contribute to polyp formation and
tumorgenesis through various mechanisms, such as loss
of growth arrest, apoptosis, and loss of cell polarity.
Additional studies are needed to address these
questions.
A genotype-phenotype correlation has been sought in
PJS. Schumacher et al. [16] suggested that in-frame
mutations in the domains that encode the protein and
ATP binding and catalysis (I-VIA) are rarely associated
with cancer. Moreover, missense mutations in the
C-terminus and in the domains for substrate recognition
( V I B - V I I I )s e e mt ob em o r ea ssociated with malignan-
cies, and patients with breast carcinomas predominantly
had truncating mutations. Mehenni et al. [13] suggested
that there was a higher risk of cancer in cases with
mutations in exon 6 of the STK11 gene. In a large ana-
lysis of 240 PJS patients with STK11 mutations, no dif-
ference was observed between individuals with missense
and truncating mutations or between familial and spora-
dic cases, although it was suggested that there was a
higher risk of cancer in individuals with mutations in
exon 3 of the gene. Hearle et al. [2] extended this study
by analyzing a total of 419 PJS patients, of whom 297
had documented mutations. In that study, it was found
that the type and site of mutation did not influence can-
cer risk.
Conclusion
In our current study, we identified the novel mutation, p.
Q302X, which was associated with cancers in both Chi-
nese families where it was identified. Members of PJS
families are at risk of developing the disease. Identifica-
tion of a STK11 gene mutation in an index patient offers
the possibility of a predictive diagnosis in PJS pedigrees.
Furthermore, a possible genotype-phenotype correlation,
especially concerning the risk of gastrointestinal and
extraintestinal cancers, would be of particular clinical
interest.
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Figure 3 Structural modeling of the wild-type and mutant proteins. The STK11 protein is mainly comprised of three major domains: the
N-terminal non-catalytic domain in red, the catalytic kinase domain in green, and the C-terminal non-catalytic regulatory domain in blue. The
mutation, p.Q302X, leads to partial loss of the kinase domain and complete loss of the C-terminal end of the a-helix.
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